ArticleMucosal immunology2019
Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis.
Article in Mucosal immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- Cohousing or cross-fostering followed by cohousing does not normalize the microbiomes of genetically distinct adult mice.Cell reports · 2025Article
- Neutralizing gut-derived lipopolysaccharide as a novel therapeutic strategy for severe leptospirosis.eLife · 2024Article
- Effect of Polycan, a β-Glucan fromInternational journal of molecular sciences · 2023Article
- Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis.Nature communications · 2023Article
- Oral Administration ofMicroorganisms · 2023Article
- Gut microbiota involved in leptospiral infections.The ISME journal · 2022Article
- Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.Journal for immunotherapy of cancer · 2022Article
- Pathogenic or Therapeutic: The Mediating Role of Gut Microbiota in Non-Communicable Diseases.Frontiers in cellular and infection microbiology · 2022Review
- NLRP3 Phospho-residue Mapping by Phospho Dot Blots.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Protective Effect of Tuna Bioactive Peptide on Dextran Sulfate Sodium-Induced Colitis in Mice.Marine drugs · 2021Article
- Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development.The Journal of clinical investigation · 2021Article
- Fish Oil, Cannabidiol and the Gut Microbiota: An Investigation in a Murine Model of Colitis.Frontiers in pharmacology · 2020Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 2 countries.
Funding
Abstract
Fecal microbiota transfer (FMT) is a very efficient approach for the treatment of severe and recurring C. difficile infections. However, the beneficial effect of FMT in other disorders such as ulcerative colitis (UC) or Crohn's disease remains unclear. Furthermore, it is currently unknown how disease-associated genetic variants in donors or recipients influence the effect of FMT. We found that bacteria-transfer from wild-type (WT) donors via cohousing was efficient in inducing recovery from colitis in WT mice, but not in mice deficient in protein-tyrosine phosphatase non-receptor type 22 (PTPN22), a known risk gene for several chronic inflammatory diseases. Also cohousing of PTPN22-deficient mice with diseased WT mice failed to induce faster recovery. Our data indicate that the genetic background of the donor and the recipient influences the outcome of microbiota transfer, and offers a potential explanation why transfer of fecal microbes from some, but not all donors is efficient in UC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.